Teijin (3401) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
13 Jun, 2025Executive summary
Revenue for Q1 FY2024 rose 11.5% year-over-year to ¥255.3 billion, with adjusted operating income up 115.7% to ¥10.4 billion and net profit attributable to owners up 110.2% to ¥4.5 billion.
The company adopted IFRS for the first time this quarter, restating prior results for comparability.
Discontinued operations reflect the planned divestiture of the IT business (Infocom), with related assets and liabilities classified as held for sale.
Financial highlights
Gross profit increased to ¥63.4 billion from ¥58.3 billion year-over-year, with operating income up to ¥8.0 billion from ¥4.6 billion.
Profit before tax rose 58.8% to ¥8.4 billion, and comprehensive income was ¥20.4 billion, down 14.3% due to lower other comprehensive income.
Basic EPS doubled to ¥23.12 from ¥11.01 year-over-year.
Net cash provided by operating activities was ¥8.6 billion, reversing a negative ¥5.9 billion last year.
Outlook and guidance
FY2024 revenue forecast is ¥1,010 billion (+5.2% YoY), with adjusted operating income of ¥23 billion (+4.8%).
Operating income forecast is ¥19 billion; profit attributable to owners and EPS guidance remain undecided pending further review.
Dividend outlook maintained at ¥30 per share for FY2024.
Latest events from Teijin
- Innovative materials and a niche-focused strategy target rapid growth in batteries, semiconductors, and hydrogen.3401
Investor presentation27 Feb 2026 - Revenue and profit fell on impairments and divestitures, but Healthcare grew and dividend is stable.3401
Q3 202623 Feb 2026 - Profit and revenue growth offset healthcare headwinds, with rare disease and home care focus.3401
Q3 202523 Dec 2025 - Growth centers on high-value, sustainable solutions and global market expansion.3401
Investor Day 202519 Dec 2025 - Major impairment and business transfer drive net loss; outlook cut, dividend steady.3401
Q2 20261 Dec 2025 - FY2024 saw profit recovery and portfolio transformation; higher FY2025 income expected.3401
Q4 202520 Nov 2025 - Profits and revenue fell in Q1 FY2025, but full-year outlook and dividend remain steady.3401
Q1 20265 Aug 2025 - Teijin accelerates healthcare growth with a focus on rare diseases, home care, and innovation.3401
Investor Update13 Jun 2025 - Impairment losses offset strong 1H growth; asset sales and restructuring support FY2024 outlook.3401
Q2 202513 Jun 2025